Daniel Kraft M.D.

A high-energy, highly visual signature keynote for healthcare, business, and investor audiences.

Accelerating, often exponential technologies are converging to make healthcare more predictive, personalized, and connected. In his signature keynote, Dr. Daniel Kraft takes audiences on a fast-paced, highly visual tour of foundation models and agentic AI, wearables, multi-omics and liquid biopsy, robotics, synthetic biology, and regenerative medicine, showing why the biggest shifts happen where these advances meet: earlier detection, more personalized therapies, longer healthspan, and broader access. 

His Now, Near and Next framework separates what is ready today from what is emerging and what is further out, with examples built for the audience in the room. Daniel makes exponential thinking concrete, challenging linear assumptions built on yesterday’s capabilities. He argues that the real enemy is friction, not technology, and that AI used well can return time and attention to clinicians and patients instead of replacing them. Audiences leave inspired about what is possible and clear on what they can do about it, starting now.

For clinical, health system, biopharma, payer, and healthcare technology audiences.

Generative, multimodal, and agentic AI are arriving in healthcare faster than most organizations can absorb them. Dr. Daniel Kraft offers a grounded look at where these tools are delivering value today, where the evidence is still thin, and where the claims outrun the capability. Applications span clinical documentation, decision support, diagnostics, patient engagement, and enterprise operations. 

The harder question is what separates real deployment from pilots that never scale. Daniel examines the requirements: usable data, clinical and operational validation, workflow integration, governance, workforce readiness, and a payment model that works, with human judgment and accountability kept in the loop. He makes the case for intelligence amplification rather than automation anxiety, and for redesigning work rather than bolting AI onto broken processes. Tailored to clinical, health system, biopharma, payer, and technology audiences, the session leaves participants knowing which applications to back first, what to ask before scaling any of them, and how to prepare their teams.

For biopharma leadership, R&D, commercial, medical affairs, and market access teams.

AI is changing the economics of discovering and developing therapies. Dr. Daniel Kraft explores applications across target identification, molecular design, trial design and site selection, synthetic control arms, and regulatory submission, and treats the AI and digitally enabled patient journey as one connected layer: shortening time to diagnosis, finding patients upstream across records and claims, and understanding adherence and response once therapy begins. 

The discussion extends to commercial, medical affairs, and market access, where the same tools are reshaping how companies reach clinicians and patients. Daniel’s central argument is that when everyone can buy the same models, the companies with a differentiated data position, and the ability to use it, will separate from the rest. Tailored to biopharma leadership, R&D, commercial, and medical affairs teams, the session leaves leaders with a clear read on their own data position, the validation bar their AI claims should meet, and where this belongs on the management agenda.

Scientific progress creates possibilities; adoption decides which become durable businesses. Dr. Daniel Kraft brings the perspective of a physician-scientist, Kauffman Fellow, and general partner at Continuum Health Ventures to how AI, advanced diagnostics, longevity, and new models of care are rewriting business models across healthcare delivery, biopharma, and consumer health. 

Using the Now, Near and Next framework, Daniel shows how to read the evidence behind an emerging opportunity, and how reimbursement, workflow fit, and data advantage decide which companies actually get there. He explores what this means for incumbents and challengers alike as care settings shift and consumer expectations move faster than the system does. Customized to the sectors in the room, the session leaves investors with Now, Near and Next applied to their own horizons and portfolio strategy, a sharper line between technical promise and commercial readiness, and better diligence questions.

For consumer health, wellness, employer, payer, and longevity-focused audiences. A stem cell biologist trained in hematology, oncology and bone marrow transplantation, Daniel brings hands-on experience in regenerative medicine and clinical trials, and a clinician’s eye for separating longevity science from longevity marketing.

Longer life is only part of the goal; healthspan is about the years people live in good health. Dr. Daniel Kraft, a physician and stem cell biologist with experience in regenerative medicine and clinical trials, explores the shift from treating illness after it appears toward proactive, personalized health, with consumers reshaping prevention, monitoring, and access without waiting for permission from the system. 

He examines what the evidence supports across metabolic health, sleep, continuous monitoring, and consumer diagnostics, and what it does not, then looks ahead to emerging science worth watching: cellular senescence and reprogramming, regenerative and stem cell approaches, and gene-based therapies. For consumer health, employer, payer, wellness, and longevity audiences, the session separates longevity science from longevity marketing, while keeping access and the behavioral and social factors no wearable can measure firmly in view.

For diagnostics, laboratory, imaging, pathology, and life sciences audiences. 

Wearables, digital biomarkers, at-home testing, and low-cost personal omics reveal what is happening between clinical visits. Dr. Daniel Kraft explores how these tools, alongside liquid biopsy, multi-cancer early detection, computational pathology, and AI-assisted imaging, are moving detection toward stage zero, before symptoms appear and before disease takes hold. 

The session examines both the promise and the limits of earlier detection, and what it means when the lab moves from the end of the workup to the front of prediction. Key questions include who should be tested, how findings are validated and interpreted, what follow-up is needed, and whether earlier detection improves outcomes. Tailored to diagnostics, laboratory, imaging, pathology, and life sciences audiences, it leaves participants with a practical test for any new diagnostic: does better detection lead to appropriate action and measurable patient benefit?

For health systems, provider organizations, and care delivery audiences.

Prevention, diagnostics, and selected acute care are moving beyond the hospital and the clinic. Dr. Daniel Kraft explores what this shift means for health systems, clinicians, and patients, and what the hospital becomes as a result. Examples include remote monitoring, home diagnostics, virtual care, and hospital-at-home programs. 

The discussion examines the evolving clinician role, from the virtualist to AI-augmented care teams, and what that demands of training and staffing models. It also looks squarely at the operational reasons promising programs stall before they scale, from patient selection and escalation pathways to workflow, reimbursement, and regulation. Tailored to health system and care delivery audiences, the session leaves leaders with a clear view of which services can move closer to patients and what it takes to deliver them safely, sustainably, and at scale.

A closed-door, facilitated strategy session for boards and executive leadership teams, drawing on Daniel’s role as founding faculty and chair of medicine at Singularity University and more than a decade leading Exponential Medicine, now NextMed Health. 

Boards and executive teams need a clear view of what their organization could become as technologies converge and accelerate. In this facilitated, closed-door session, Dr. Daniel Kraft applies his Now, Near and Next framework to the organization’s specific strategy, set against what competitors are actually doing, drawing on more than a decade leading Medicine and NextMed Health. 

The discussion makes exponential thinking practical: challenging linear assumptions and focusing on where to act, what to test, and what to monitor. It starts with the data question, what the organization uniquely holds, whether it is governed and usable, and whether AI claims meet the same standard as clinical or commercial claims, then turns to talent, leadership, and governance gaps, including the questions directors should ask and what management should report. Available as a two-to-three-hour session or part of an agreed half-day or full-day agenda, the engagement includes a written summary of agreed priorities, with preparation and scope confirmed in advance. Recent sessions include the boards of Argenx and Atrium Health and the executive leadership teams of Teva and Roche.